Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

by · The Cerbat Gem

Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 8,400 shares, a growth of 110.0% from the October 15th total of 4,000 shares. Based on an average daily volume of 29,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the company’s stock are short sold.

Barinthus Biotherapeutics Stock Down 29.7 %

NASDAQ BRNS traded down $0.41 during trading hours on Friday, hitting $0.97. The company’s stock had a trading volume of 263,301 shares, compared to its average volume of 24,928. The stock has a fifty day moving average of $1.30 and a 200 day moving average of $1.54. The firm has a market capitalization of $38.36 million, a P/E ratio of -0.64 and a beta of -0.59. Barinthus Biotherapeutics has a twelve month low of $0.88 and a twelve month high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million for the quarter. During the same quarter last year, the company posted ($0.37) earnings per share. On average, analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on BRNS. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Friday, November 8th. Alliance Global Partners reduced their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Check Out Our Latest Analysis on Barinthus Biotherapeutics

Institutional Trading of Barinthus Biotherapeutics

Several hedge funds have recently bought and sold shares of BRNS. Alphabet Inc. acquired a new stake in shares of Barinthus Biotherapeutics during the second quarter worth $2,119,000. Catalina Capital Group LLC acquired a new stake in Barinthus Biotherapeutics during the 2nd quarter valued at $25,000. Ipswich Investment Management Co. Inc. bought a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth about $32,000. M&G Plc acquired a new stake in Barinthus Biotherapeutics during the 2nd quarter worth approximately $7,276,000. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Barinthus Biotherapeutics in the first quarter valued at about $1,292,000. 25.20% of the stock is currently owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

See Also